NanJing Pharmaceutical (600713) Fundamentals 2026 — P/E 10.2x, Revenue Analysis | SniperIQ
NanJing Pharmaceutical (600713) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥6.5B, trading at ¥4.95 on the SHH. This SniperIQ fundamentals page covers NanJing Pharmaceutical's valuation (P/E 10.2x, P/B 0.9x), profitability (net margin 1.1%), revenue (¥55.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NanJing Pharmaceutical's market cap?
NanJing Pharmaceutical (600713) has a market capitalization of approximately ¥6.5B, trading at ¥4.95 on the SHH. Market cap moves with the live share price.
What is NanJing Pharmaceutical's P/E ratio?
NanJing Pharmaceutical's trailing twelve-month P/E ratio is 10.2x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is NanJing Pharmaceutical?
NanJing Pharmaceutical runs a net profit margin of 1.1%, a gross margin of 6.2%, and an operating margin of 2.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NanJing Pharmaceutical generate?
NanJing Pharmaceutical reported revenue of ¥55.0B for fiscal year 2025, with net income of ¥625M and earnings per share (EPS) of 0.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NanJing Pharmaceutical pay a dividend?
NanJing Pharmaceutical offers a trailing dividend yield of about 3.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is NanJing Pharmaceutical financially healthy?
NanJing Pharmaceutical carries a debt-to-equity ratio of 1.26x and a current ratio of 1.45x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NanJing Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NanJing Pharmaceutical (600713) the key facts are: market cap ¥6.5B, P/E 10.2x, revenue ¥55.0B, 52-week range 4.81-6.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track NanJing Pharmaceutical's full fundamentals live
Get NanJing Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.